TrialHuman vaccines & immunotherapeutics2025

Lot-to-lot consistency, immunogenicity, and safety of a 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy adults aged 40-65 years: A randomized, double-blind, controlled, phase IV clinical trial.

Yunong Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.